EMMESSAR BIOTECH & NUTRITION LTD.

Emmessar Biotech & Nutrition Ltd has dispatched communications to members without registered email addresses, providing a web-link to access the complete Annual Report for FY 2025-26 and the Notice for the 34th Annual General Meeting. The AGM is scheduled for September 29, 2026, at 10:30 a.m., with e-voting available from September 26 to September 28, 2026. The company also reminded shareholders holding physical shares to update KYC details as per SEBI regulations, including PAN, address, mobile number, bank details, and signature, and encouraged them to register their email IDs for online services.

Emmessar Biotech & Nutrition Ltd has dispatched communications to members without registered email addresses, providing a web-link to access the complete Annual Report for FY 2025-26 and the Notice for the 34th Annual General Meeting. This action complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The AGM is scheduled for September 29, 2026, at 10:30 a.m., with e-voting available from September 26 to September 28, 2026. The company also reminded shareholders holding physical shares to update KYC details as per SEBI's Master Circular.

Emmessar Biotech & Nutrition Ltd. has issued a notice for its 34th Annual General Meeting (AGM) to be held on September 29, 2026, via Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The meeting will commence at 10:30 a.m. Key agenda items include the adoption of Audited Financial Statements for the Financial Year ended March 31, 2026, the re-appointment of Mr. Jeyavel Balaiah Nadar as a Director, and the re-appointment of Mr. Srinivasa Raghavan Mathurakavi Ayyangar as Managing Director for a further period of 5 years. The proposed re-appointment of the Managing Director includes specific remuneration details and terms.

Emmessar Biotech & Nutrition Ltd. has announced its 34th Annual General Meeting (AGM) to be held on September 29, 2026, via Video Conferencing. The agenda includes the adoption of the Audited Financial Statements for the fiscal year ended March 31, 2026, the re-appointment of Mr. Jeyavel B. Nadar as a Director, and the re-appointment of Mr. Srinivasa Raghavan Mathurakavi Ayyangar as Managing Director for a further period of five years. The company also provided details on the proposed remuneration and terms for the Managing Director's reappointment.

Makers Laboratories Limited has published its unaudited consolidated financial results for the quarter ended June 30, 2026. The company reported a total income from operations of ₹1,127.46 Lacs for the quarter, a slight increase from ₹1,018.75 Lacs in the same period last year. Profit before tax stood at ₹(116.12) Lacs, compared to ₹(125.72) Lacs in the prior year's quarter. Net profit after tax for the quarter was ₹(96.37) Lacs, an improvement from ₹(107.50) Lacs year-on-year. The full financial results are available on the BSE website and the company's website.

Emmessar Biotech & Nutrition Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved these results, which were reviewed by the Audit Committee. A limited review report from statutory auditors M/s. V. Nagarajan & Co. was also provided. The company also announced its 34th Annual General Meeting (AGM) will be held on September 29, 2025, via video conferencing. The cutoff date for remote e-voting is September 22, 2026, with voting commencing on September 26, 2026, and concluding on September 28, 2026.

Emmessar Biotech & Nutrition Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved these results on August 7, 2026. A limited review report from statutory auditors M/s. V. Nagarajan & Co. was also provided. The company also announced its 34th Annual General Meeting (AGM) will be held on September 29, 2025, through video conferencing, with a cut-off date of September 22, 2026, for remote e-voting. The remote e-voting period is scheduled from September 26 to September 28, 2026.

Emmessar Biotech & Nutrition Ltd has announced that its Board of Directors will convene on August 7, 2026, in Mumbai. The primary agenda item for this meeting is to consider and approve the unaudited financial results for the quarter ended June 30, 2026. Additionally, the company has informed that the trading window, which was closed as per SEBI (Prohibition of Insider Trading) Regulations, 2015, will remain closed until August 9, 2026.

Emmessar Biotech & Nutrition Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 01, 2026, and will continue until 48 hours after the financial results for the quarter ending June 30, 2026, are made public. This measure is in compliance with SEBI's Prohibition of Insider Trading Regulations, 2015, aimed at preventing potential misuse of unpublished price-sensitive information.

Emmessar Biotech & Nutrition Ltd's Board of Directors approved the audited standalone financial results for the year ended March 31, 2026, following a review by the Audit Committee. The board meeting, held on May 12, 2026, also included a declaration on the audit report with an unmodified opinion from V. Nagarajan & Co., Chartered Accountants.